Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: Analysis from the EMPHASIS-HF trial

European Heart Journal

Volumn 36, Issue 34, 2015, Pages 2310-2317

  Girerd, Nicolas ^a   Collier, Tim ^b   Pocock, Stuart ^b   Krum, Henry ^c   McMurray, John J ^d   Swedberg, Karl ^e,f   Van Veldhuisen, Dirk J ^g   Vincent, John ^h   Pitt, Bertram ⁱ   Zannad, Faiez ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h PFIZER INC   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

EMPHASIS HF; Eplerenone; Hospitalization; Systolic heart failure; Timing; Treatment effect

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; PLACEBO; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); DEATH; DISEASE CLASSIFICATION; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZATION; SYSTOLIC HEART FAILURE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FOLLOW UP; HEART FAILURE, SYSTOLIC; HOSPITALIZATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HOSPITALIZATION; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PATIENT READMISSION; SECONDARY PREVENTION; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84941197910     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv273     Document Type: Article

References (33)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181.
2. Corrao G, Ghirardi A, Ibrahim B, Merlino L, Maggioni AP. Burden of new hospital-ization for heart failure: a population-based investigation from Italy. Eur J Heart Fail 2014;16:729-736.
3. Vaduganathan M, Butler J, Fonarow GC, Gheorghiade M. Progress or lack of progress in hospitalized heart failure. Expert Rev Cardiovasc Ther 2013;11:1079-1083.
4. Gheorghiade M, Shah AN, Vaduganathan M, Butler J, Bonow RO, Rosano GM, Taylor S, Kupfer S, Misselwitz F, Sharma A, Fonarow GC. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives. Heart Fail Clin 2013;9:285-290, v-vi.
5. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;33:1787-1847.
6. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-717.
8. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA 2009;302: 1658-1665.
9. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy C, Young JB. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Am Heart J 2007;153:82.e111.
10. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013;61:391-403.
11. Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J 2013;34: 2823-2829.
12. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Pina IL, Soler-Soler J, Swedberg K. Practical recommendations for the use of ace inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005;7:710-721.
13. Heart Failure Society of America (HFSA) Practice Guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail 1999;5:357-382.
14. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carve-dilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;43: 1534-1541.
15. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. J Card Fail 2007;13:722-731.
16. Ahmed A, Centor RM, Weaver MT, Perry GJ. A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications. Am Heart J 2005;149: 737-743.
17. Fonarow GC. The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. Rev Cardiovasc Med 2002;3(Suppl 3): S2-S10.
18. Forman DE, Cannon CP, Hernandez AF, Liang L, Yancy C, Fonarow GC. Influence of age on the management of heart failure: findings from Get with the Guidelines-Heart Failure (GWTG-HF). Am Heart J 2009;157:1010-1017.
19. Fonarow GC. Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF. Rev Cardiovasc Med 2004;5(Suppl 1):S45-S54.
20. Heidenreich PA, Hernandez AF, Yancy CW, Liang L, Peterson ED, Fonarow GC. Get with the guidelines program participation, process of care, and outcome for medicare patients hospitalized with heart failure. Circ Cardiovasc Qual Outcomes 2012;5:37-43.
21. Krantz MJ, Ambardekar AV, Kaltenbach L, Hernandez AF, Heidenreich PA, Fonarow GC, Get with the Guidelines Steering C, Hospitals. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get with the Guidelines-Heart Failure). Am J Cardiol 2011;107: 1818-1823.
22. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy C, Young JB. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007;297:61-70.
23. Gheorghiade M. Reassessing treatment of acute heart failure syndromes: the Adhere Registry. Eur Heart J Suppl 2005;7:B13-B19.
24. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from organized program to initiate lifesaving treatment in hospitalized patients with heart failure). Am J Cardiol 2008;102:1524-1529.
25. Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Setoguchi S, Hernandez AF, Fonarow GC. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J 2013;165:979-986 e971.
26. Howlett JG, Ezekowitz JA, Podder M, Hernandez AF, Diaz R, Dickstein K, Dunlap ME, Corbalan R, Armstrong PW, Starling RC, O'Connor CM, Califf RM, Fonarow GC, Investigators A-H. Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the Acute Study Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial (ASCEND-HF). Circ Cardiovasc Qual Outcomes 2013;6:534-542.
27. Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ, National Heart Failure Audit Team for E, Wales. The National Heart Failure Audit for England and Wales 2008-2009. Heart 2011;97:876-886.
28. Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Rosas SE, Zhao X, Schwamm LH, Bhatt DL. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol 2013;61:35-40.
29. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the randomized aldac-tone evaluation study. N Engl J Med 2004;351:543-551.
30. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure). J Am Coll Cardiol 2013;62:1585-1593.
31. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Gheorghiade M. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010;3:314-325.
32. Albaghdadi M, Gheorghiade M, Pitt B. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Eur Heart J 2011;32: 2626-2633.
33. Girerd N, Pang PS, Swedberg K, Fought A, Kwasny MJ, Subacius H, Konstam MA, Maggioni A, Gheorghiade M, Zannad F, Investigators E. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail 2013;15:1228-1235.